Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003027 | Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 3 | 482 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003444 | Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin | completed | Phase 3 | 167 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 |
| clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT01359956 | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma(SICOG 0109) | completed | Phase 3 | 269 | National Cancer Institute, NaplesOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT05783882 | Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma(FLAT) | unknown | Phase 3 | 114 | BiocadINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03294330 | SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer(SPYX) | completed | Phase 3 | 35 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | terminated | Phase 3 | 481 | Idera Pharmaceuticals, Inc.INDUSTRY | 11 | Nov 8, 2022 | clinicaltrials |
| NCT02843386 | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma(FOTEADJ) | completed | Phase 3 | 302 | Institut CurieOTHER | 2 | Aug 31, 2022 | clinicaltrials |
| NCT01721772 | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma(CheckMate 066) | completed | Phase 3 | 418 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 12, 2022 | clinicaltrials |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | completed | Phase 3 | 387 | Bristol-Myers SquibbINDUSTRY | 13 | Jun 24, 2022 | clinicaltrials |
| NCT01689519 | A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma(coBRIM) | completed | Phase 3 | 495 | Hoffmann-La RocheINDUSTRY | 19 | May 2, 2022 | clinicaltrials |
| NCT01721746 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | completed | Phase 3 | 405 | Bristol-Myers SquibbINDUSTRY | 14 | Apr 19, 2022 | clinicaltrials |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | terminated | Phase 3 | 20 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 5 | Jan 19, 2022 | clinicaltrials |
| NCT03068455 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma(CheckMate 915) | completed | Phase 3 | 1,844 | Bristol-Myers SquibbINDUSTRY | 19 | Sep 20, 2021 | clinicaltrials |
| NCT03329846 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | completed | Phase 3 | 20 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 9, 2021 | clinicaltrials |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | completed | Phase 3 | 93 | Delcath Systems Inc.INDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02599402 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma(CheckMate 401) | completed | Phase 3 | 533 | Bristol-Myers SquibbINDUSTRY | 12 | Jun 15, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT01584648 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | completed | Phase 3 | 423 | Novartis PharmaceuticalsINDUSTRY | 14 | Feb 17, 2021 | clinicaltrials |
| NCT02905266 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | completed | Phase 3 | 106 | Bristol-Myers SquibbINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01280565 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | terminated | Phase 3 | 134 | AB ScienceINDUSTRY | 7 | Nov 5, 2020 | clinicaltrials |
| NCT01826864 | Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma | withdrawn | Phase 3 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01866319 | Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | completed | Phase 3 | 834 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 2, 2020 | clinicaltrials |
| NCT02545075 | A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | completed | Phase 3 | 182 | Bristol-Myers SquibbINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT00057616 | Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. | completed | Phase 3 | 274 | CelgeneINDUSTRY | 9 | Nov 8, 2019 | clinicaltrials |
| NCT00864253 | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | completed | Phase 3 | 529 | CelgeneINDUSTRY | 9 | Oct 30, 2019 | clinicaltrials |
| NCT01088737 | Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | unknown | Phase 2 / Phase 3 | 60 | Medical University of GrazOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | completed | Phase 3 | 831 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 31, 2019 | clinicaltrials |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | terminated | Phase 2 / Phase 3 | 126 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 24, 2019 | clinicaltrials |
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
| NCT01875653 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | terminated | Phase 3 | 4 | Lisata Therapeutics, Inc.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases | terminated | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | terminated | Phase 3 | 336 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 17, 2018 | clinicaltrials |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | completed | Phase 3 | 322 | GlaxoSmithKlineINDUSTRY | 19 | Apr 5, 2018 | clinicaltrials |
| NCT03435302 | HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma | unknown | Phase 3 | 204 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01264874 | MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients(MelaViD) | terminated | Phase 3 | 150 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT00019682 | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | completed | Phase 3 | 185 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00091572 | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) | completed | Phase 3 | 859 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2017 | clinicaltrials |
| NCT00200577 | Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma(TIL) | completed | Phase 3 | 70 | Nantes University HospitalOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00204529 | Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB | completed | Phase 3 | 901 | University Hospital TuebingenOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00680225 | Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma | completed | Phase 3 | 10 | New England Retina AssociatesOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT01974752 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)(SUMIT) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 11 | Jan 5, 2017 | clinicaltrials |
| NCT02427893 | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | withdrawn | Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02962947 | MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | unknown | Phase 2 / Phase 3 | 546 | Azienda Sanitaria di FirenzeOTHER | 0 | Nov 15, 2016 | clinicaltrials |
| NCT01006980 | A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | completed | Phase 3 | 675 | Hoffmann-La RocheINDUSTRY | 12 | Sep 28, 2016 | clinicaltrials |
| NCT00769704 | Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | completed | Phase 3 | 437 | BioVex LimitedINDUSTRY | 4 | Jul 13, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 22, 2023source: clinicaltrials